LEO pharma
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | - | - | - | 1.3b | 10.6b | 1.5b |
% growth | - | - | - | - | 702 % | (86 %) |
Profit | - | - | - | (649m) | (4.1b) | (481m) |
% profit margin | - | - | - | (49 %) | (39 %) | (32 %) |
R&D budget | 254m | 396m | 408m | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
€450m | Growth Equity VC | ||
Total Funding | €450m |
Related Content
Recent News about LEO pharma
EditLEO Pharma is a global pharmaceutical company specializing in dermatology, focusing on innovative treatments for skin diseases. The company operates in the healthcare market, primarily serving patients, healthcare professionals, and industry partners. LEO Pharma's business model revolves around research and development, leveraging its Open Innovation platform to collaborate with external partners. This platform allows partners to test proprietary compounds in advanced biological assays at no cost, without business obligations, and with full ownership of the data. The company generates revenue through the development and commercialization of dermatological drugs, as well as through strategic partnerships and collaborations. LEO Pharma's commitment to innovation and collaboration positions it as a leader in the dermatology sector.
Keywords: dermatology, bioassays, open innovation, skin diseases, pharmaceutical, partnerships, R&D, healthcare, drug development, collaboration.